{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T18:31:30Z","timestamp":1793644290494,"version":"4.5.1"},"reference-count":55,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,9]],"date-time":"2023-05-09T00:00:00Z","timestamp":1683590400000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["rpthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research and Practice in Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.rpth.2023.100179","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T04:24:16Z","timestamp":1684211056000},"page":"100179","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Antithrombin-lowering in hemophilia: a closer look at fitusiran"],"prefix":"10.1016","volume":"7","author":[{"given":"Guy","family":"Young","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Lenting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy E.","family":"Croteau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Nolan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alok","family":"Srivastava","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rpth.2023.100179_bib1","series-title":"Physiology, coagulation pathways","author":"Chaudhry","year":"2021"},{"key":"10.1016\/j.rpth.2023.100179_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2019.05.006","article-title":"The central role of thrombin in bleeding disorders","volume":"38","author":"Negrier","year":"2019","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2023.100179_bib3","series-title":"Physiology, hemostasis. Florida","author":"LaPelusa","year":"2022"},{"key":"10.1016\/j.rpth.2023.100179_bib4","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1055\/s-0037-1615947","article-title":"A\u00a0cell-based model of hemostasis","volume":"85","author":"Hoffman","year":"2001","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100179_bib5","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1038\/202498a0","article-title":"An enzyme cascade in the blood clotting mechanism, and its function as a biochemical amplifier","volume":"202","author":"Macfarlane","year":"1964","journal-title":"Nature"},{"key":"10.1016\/j.rpth.2023.100179_bib6","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1126\/science.145.3638.1310","article-title":"Waterfall sequence for intrinsic blood clotting","volume":"145","author":"Davie","year":"1964","journal-title":"Science"},{"key":"10.1016\/j.rpth.2023.100179_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/S0268-960X(03)90000-2","article-title":"A\u00a0cell-based model of coagulation and the role of factor VIIa","volume":"17","author":"Hoffman","year":"2003","journal-title":"Blood Rev"},{"key":"10.1016\/j.rpth.2023.100179_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.100179_bib9","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S0140-6736(15)01123-X","article-title":"The past and future of haemophilia: diagnosis, treatments, and its complications","volume":"388","author":"Peyvandi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.rpth.2023.100179_bib10","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1182\/asheducation-2016.1.657","article-title":"Hemophilia and inhibitors: current treatment options and potential new therapeutic approaches","volume":"2016","author":"Meeks","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"10.1016\/j.rpth.2023.100179_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3324\/haematol.2019.239160","article-title":"Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet study","volume":"106","author":"Male","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.rpth.2023.100179_bib12","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/jth.14296","article-title":"The future of bypassing agents for hemophilia with inhibitors in the era of novel agents","volume":"16","author":"Shapiro","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100179_bib13","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1055\/s-0037-1613258","article-title":"The thrombogram in rare inherited coagulation disorders: its relation to clinical bleeding","volume":"88","author":"Al Dieri","year":"2002","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100179_bib14","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1016\/j.thromres.2004.06.017","article-title":"Phenotyping the haemostatic system by thrombography\u2014potential for the estimation of thrombotic risk","volume":"114","author":"Regnault","year":"2004","journal-title":"Thromb Res"},{"key":"10.1016\/j.rpth.2023.100179_bib15","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood.V94.7.2169.419k22_2169_2178","article-title":"\u201cNormal\u201d thrombin generation","volume":"94","author":"Butenas","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.100179_bib16","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1111\/j.1365-2141.2007.06693.x","article-title":"Contribution of natural anticoagulant and fibrinolytic factors in modulating the clinical severity of haemophilia patients","volume":"138","author":"Shetty","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.rpth.2023.100179_bib17","first-page":"516","article-title":"Inherited antithrombin deficiency causing thrombophilia","volume":"13","author":"Egeberg","year":"1965","journal-title":"Thromb Diath Haemorrh"},{"key":"10.1016\/j.rpth.2023.100179_bib18","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood-2018-07-820712","article-title":"New therapies using nonfactor products for patients with hemophilia and inhibitors","volume":"133","author":"Nogami","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.100179_bib19","first-page":"457","article-title":"Non-factor replacement therapy for haemophilia: a current update","volume":"16","author":"Franchini","year":"2018","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2023.100179_bib20","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1111\/jth.15682","article-title":"A\u00a0novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: results from safety studies in cynomolgus monkeys","volume":"20","author":"Lauritzen","year":"2022","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100179_bib21","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1111\/hae.14167","article-title":"Practical considerations for nonfactor-replacement therapies in the treatment of haemophilia with inhibitors","volume":"27","author":"Jimenez-Yuste","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.100179_bib22","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.ejmhg.2017.10.004","article-title":"Determinants and modifiers of bleeding phenotypes in haemophilia-A: general and tropical perspectives","volume":"19","author":"Ibrahim","year":"2018","journal-title":"Egypt J Med Hum Genet"},{"key":"10.1016\/j.rpth.2023.100179_bib23","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1111\/j.1365-2516.2009.01994.x","article-title":"Thrombin generation and bleeding in haemophilia A","volume":"15","author":"Brummel-Ziedins","year":"2009","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.100179_bib24","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/hae.12110","article-title":"Monitoring rFVIII prophylaxis dosing using global haemostasis assays","volume":"19","author":"Al Hawaj","year":"2013","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.100179_bib25","doi-asserted-by":"crossref","first-page":"117","DOI":"10.4103\/IJPM.IJPM_336_19","article-title":"Clinical utility of activated partial thromboplastin time clot waveform analysis and thrombin generation test in the evaluation of bleeding phenotype in hemophilia A","volume":"64","author":"Dave","year":"2021","journal-title":"Indian J Pathol Microbiol"},{"key":"10.1016\/j.rpth.2023.100179_bib26","first-page":"314","article-title":"Achieving and maintaining an optimal trough level for prophylaxis in haemophilia: the past, the present and the future","volume":"12","author":"Jimenez-Yuste","year":"2014","journal-title":"Blood Transfus"},{"key":"10.1016\/j.rpth.2023.100179_bib27","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1055\/s-2008-1066024","article-title":"The phenotypic heterogeneity of severe hemophilia","volume":"34","author":"Jayandharan","year":"2008","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.rpth.2023.100179_bib28","doi-asserted-by":"crossref","first-page":"5314","DOI":"10.1182\/blood-2008-10-184879","article-title":"Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives","volume":"113","author":"Lijfering","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.100179_bib29","first-page":"9","article-title":"Milder clinical presentation of haemophilia A with severe deficiency of factor VIII as measured by one-stage assay","volume":"7","author":"Ghosh","year":"2001","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.100179_bib30","first-page":"135","article-title":"An investigational RNAi therapeutic targeting antithrombin for the treatment of hemophilia A and B","volume":"9","author":"Machin","year":"2018","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.rpth.2023.100179_bib31","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1016\/j.cell.2006.12.001","article-title":"RNA interference: big applause for silencing in Stockholm","volume":"127","author":"Zamore","year":"2006","journal-title":"Cell"},{"key":"10.1016\/j.rpth.2023.100179_bib32","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1616569","article-title":"Targeting of antithrombin in hemophilia A or B with RNAi therapy","volume":"377","author":"Pasi","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.rpth.2023.100179_bib33","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3097","article-title":"Clinical advances of siRNA therapeutics","volume":"21","author":"Hu","year":"2019","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.rpth.2023.100179_bib34","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1093\/clinchem\/34.1.59","article-title":"An enzymatic method for 5-fluorocytosine","volume":"34","author":"Huang","year":"1988","journal-title":"Clin Chem"},{"key":"10.1016\/j.rpth.2023.100179_bib35","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jth.14648","article-title":"Recommendations for clinical laboratory testing for antithrombin deficiency; communication from the SSC of the ISTH","volume":"18","author":"Van Cott","year":"2020","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100179_bib36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ymthe.2017.12.021","article-title":"Advanced siRNA designs further improve in\u00a0vivo performance of GalNAc-siRNA conjugates","volume":"26","author":"Foster","year":"2018","journal-title":"Mol Ther"},{"key":"10.1016\/j.rpth.2023.100179_bib37","doi-asserted-by":"crossref","first-page":"16958","DOI":"10.1021\/ja505986a","article-title":"Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing","volume":"136","author":"Nair","year":"2014","journal-title":"J\u00a0Am Chem Soc"},{"key":"10.1016\/j.rpth.2023.100179_bib38","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1111\/j.1651-2227.1975.tb03893.x","article-title":"Antithrombin in infancy and childhood","volume":"64","author":"Catrine","year":"1975","journal-title":"Acta Paediatr Scand"},{"key":"10.1016\/j.rpth.2023.100179_bib39","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1111\/jth.15270","article-title":"Targeting of antithrombin in hemophilia A or B with investigational siRNA therapeutic fitusiran-Results of the phase 1 inhibitor cohort","volume":"19","author":"Pasi","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100179_bib40","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1182\/blood-2018-99-112998","article-title":"The role of antithrombin lowering in patients with hemophilia: hemostatic control pre- and post-fitusiran dosing interruption","volume":"132","author":"Ragni","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.100179_bib41","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.12491.1","article-title":"Emerging therapies for hemophilia: controversies and unanswered questions","volume":"7","author":"Arruda","year":"2018","journal-title":"F1000Res"},{"key":"10.1016\/j.rpth.2023.100179_bib42","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1182\/blood-2020-138424","article-title":"Reducing Antithrombin in plasma to levels observed in fitusiran-treated patients does not interfere with coagulation assays","volume":"136","author":"Wang","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.100179_bib43","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1160\/TH09-10-0732","article-title":"Heterozygous antithrombin deficiency improves in\u00a0vivo haemostasis in factor VIII-deficient mice","volume":"103","author":"Bolliger","year":"2010","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.rpth.2023.100179_bib44","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nm.3847","article-title":"An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia","volume":"21","author":"Sehgal","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.rpth.2023.100179_bib45","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1182\/blood-2022-169043","article-title":"Development of a quantitative systems pharmacology model to explore hemostatic equivalency of antithrombin lowering","volume":"140","author":"Kaddi","year":"2022","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.100179_bib54","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1111\/hae.12642","article-title":"Interpreting important health-related quality of life change using the Haem-A-QoL","volume":"21","author":"Wyrwich","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.rpth.2023.100179_bib55","series-title":"Long-term durability, safety and efficacy of fitusiran prophylaxis in people with hemophilia a or B, with or without inhibitors\u2014results from the phase II study","author":"Pipe","year":"2020"},{"key":"10.1016\/j.rpth.2023.100179_bib56","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1182\/blood-2021-150273","article-title":"Efficacy and safety of fitusiran prophylaxis, an siRNA therapeutic, in a multicenter phase 3 study (ATLAS-INH) in people with hemophilia A or B, with inhibitors (PwHI)","volume":"138","author":"Young","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.100179_bib57","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-155018","article-title":"Fitusiran, an investigational siRNA therapeutic targeting antithrombin for the treatment of hemophilia: first results from a phase 3 study to evaluate efficacy and safety in people with hemophilia a or B without inhibitors (ATLAS-A\/B)","volume":"138","author":"Srivastava","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.100179_bib58","article-title":"A phase 3 study (ATLAS-PPX) to evaluate efficacy and safety of fitusiran, an siRNA therapeutic, in people with haemophilia A or B who have switched from prior factor or bypassing agent prophylaxis","volume":"6","author":"Kenet","year":"2022","journal-title":"Res Pract Thromb Hemost"},{"key":"10.1016\/j.rpth.2023.100179_bib59","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1542\/peds.113.S3.1097","article-title":"Liver","volume":"113","author":"Pi\u00f1eiro-Carrero","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/j.rpth.2023.100179_bib60","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1182\/blood-2019-124108","article-title":"Fitusiran, an RNAi therapeutic targeting antithrombin to restore hemostatic balance in patients with hemophilia A or B with or without inhibitors: management of acute bleeding events","volume":"134","author":"Pipe","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.rpth.2023.100179_bib61","series-title":"Fitusiran, an siRNA therapeutic targeting antithrombin for the treatment of haemophilia: proposed revisions to dose and regimen as a risk mitigation for vascular thrombosis. The European Association for Haemophilia and Allied Disorders","author":"Negrier","year":"2021"},{"key":"10.1016\/j.rpth.2023.100179_bib62","author":"Pipe"},{"key":"10.1016\/j.rpth.2023.100179_bib64","first-page":"3659","article-title":"In silico modeling of the coagulation cascade and thrombin generation: simulating antithrombin (AT) lowering in hemophilia and rare bleeding disorders (RBDs)","volume":"130","author":"Sridharan","year":"2017","journal-title":"Blood"}],"container-title":["Research and Practice in Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923001528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2475037923001528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T12:26:42Z","timestamp":1762864002000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2475037923001528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S2475037923001528"],"URL":"https:\/\/doi.org\/10.1016\/j.rpth.2023.100179","relation":{},"ISSN":["2475-0379"],"issn-type":[{"value":"2475-0379","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antithrombin-lowering in hemophilia: a closer look at fitusiran","name":"articletitle","label":"Article Title"},{"value":"Research and Practice in Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rpth.2023.100179","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}],"article-number":"100179"}}